{"schema_version":"secwatch.filing_event.v1","accession":"0001826466-22-000149","form_type":"8-K","ticker":"NIKA","cik":"0001145604","company_name":"NIKA PHARMACEUTICALS, INC","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.752275+00:00","generated_at":"2026-06-21T18:05:31.206552+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Appoints Dr. Darena Stoykova Zlateva as Chief Scientific Officer effective Nov 12, 2022","bullets":["Dr. Zlateva appointed CSO of Nika Pharmaceuticals effective Nov 12, 2022.","She holds a PhD in Immunology and a medical degree; prior roles at Sofia Medical Academy and European Medical Association.","Employment contract signed with Nika Europe Ltd., in which Nika owns a 40% stake.","CSO will manage research projects, represent company at scientific forums, and formulate long-term research strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001826466-22-000149","json":"https://secwatch.observer/filing/0001826466-22-000149.json","markdown":"https://secwatch.observer/filing/0001826466-22-000149.md","text":"https://secwatch.observer/filing/0001826466-22-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1145604/000182646622000149/0001826466-22-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1145604/000182646622000149/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:05:31.206552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"576cca4509","claim":"Dr. Darena Stoykova Zlateva was appointed as Chief Scientific Officer at NIKA PHARMACEUTICALS, INC.","evidence_excerpt":"On November 12, 2022, Nika Pharmaceuticals, Inc. (the “company”) appointed Dr. Darena Stoykova Zlateva as the company’s Chief Scientific Officer (“CSO”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1145604/000182646622000149/0001826466-22-000149-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}